4-CBZ-氨基苯基硼酸 | 192804-36-7

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-CBZ-氨基苯基硼酸
• 中文别名: 4-(苄氧基氨甲酰基)苯硼酸；4-CBZ-氨基苯基)硼酸
• 英文名称: (4-(((benzyloxy)carbonyl)amino)phenyl)boronic acid
• 英文别名: [4-(benzyloxycarbonylamino)phenyl]boronic acid；4-(benzyloxycarbonylamino)phenylboronic acid；(4-Cbz-aminophenyl)boronic acid；4-Cbz-amino-phenyl boronic acid；(4-benzyloxycarbonylaminophenyl)boric acid；4-benzyloxycarbonylaminophenylboronic acid；[4-(phenylmethoxycarbonylamino)phenyl]boronic acid
• CAS: 192804-36-7
• 化学式: C₁₄H₁₄BNO₄
• 分子量: 271.08
• InChiKey: KYCQBMOJDXVNIC-UHFFFAOYSA-N

物化性质

• 熔点：
  168-169°C
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.12
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温和干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Cbz-aminophenyboronic acid
Product Name:
Synonyms: 4-(Benzyloxycarbonylamino)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Cbz-aminophenyboronic acid
Ingredient name:
CAS number: 192804-36-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H14BNO4
Molecular weight: 271.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-CBZ-氨基苯基硼酸 在 N-氯代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以92%的产率得到(4-氯苯基)-氨基甲酸苄酯
  参考文献：
  名称：

  高效多相铜催化芳基硼酸的氯脱硼，生成氯代芳烃

  摘要：

  的芳基硼酸与廉价的A高效多相铜催化chlorodeboronation Ñ氯琥珀酰亚胺（NCS）中的溶液在MeCN中的10％（摩尔）的存在下实现的大号脯氨酸官能MCM-41固定化铜（我）络合物[MCM-41 -大号-脯氨酸-CuCl]在温和的条件下，以优异的收率产生各种芳基氯化物。事实证明，该方法可耐受各种官能团，并且特别适用于将缺电子的芳基硼酸转化为芳基氯化物，这种转化在没有铜催化的情况下效率低下。可以通过简单过滤反应溶液来回收这种多相铜催化剂，并循环至少10次而不会降低活性。

  DOI：

  10.1039/c6ra25666j

文献信息

• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160326125A1

  公开（公告）日：2016-11-10

  The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used medicaments.

  本发明提供了规范中定义的Formula (I)的化合物以及包含任何此类新化合物的组合物。这些化合物是内皮酶抑制剂，可用作药物。
• [EN] SULFONE AMIDE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE<br/>[FR] COMPOSÉS BENZOTHIAZOLE À LIAISON AMIDE SULFONE UTILISÉS EN TANT QU'INHIBITEURS DE LA LIPASE ENDOTHÉLIALE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015105749A1

  公开（公告）日：2015-07-16

  The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used medicaments.

  本发明提供了规范中定义的Formula (I)的化合物以及包含任何此类新化合物的组合物。这些化合物是内皮脂酶抑制剂，可用作药物。
• Continuous Flow Palladium(II)-Catalyzed Oxidative Heck Reactions with Arylboronic Acids
  作者：Luke R. Odell、Jonas Lindh、Tomas Gustafsson、Mats Larhed

  DOI：10.1002/ejoc.201000063

  日期：2010.4

  Palladium(II)-catalyzed oxidative Heck reactions were investigated under continuous flow conditions. Selective, fast and convenient protocols for the coupling of arylboronic acids with electron-rich and electron-poor olefins were developed by using a commercially available flow reactor.

  在连续流动条件下研究了钯 (II) 催化的氧化 Heck 反应。通过使用市售流动反应器开发了用于将芳基硼酸与富电子和缺电子烯烃偶联的选择性、快速和方便的方案。
• [EN] SUBSTITUTED PHENYL CYCLOALKYL PYRROLIDINE (PIPERIDINE) SPIROLACTAMS AND AMIDES, PREPARATION AND THERAPEUTIC USE THEREOF<br/>[FR] SPIROLACTAMES ET AMIDES DE PHÉNYLCYCLOALKYLPYRROLIDINE (PIPÉRIDINE) SUBSTITUÉS, LEUR PRÉPARATION ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：SANOFI SA

  公开号：WO2011143150A1

  公开（公告）日：2011-11-17

  The present invention discloses and claims respectively a series of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (I) (Ia) and formula (Ib) as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides of formula (Ia) and (Ib), and intermediates therefor.

  本发明分别公开和声明了一系列取代苯基环烷基吡咯烷（哌啶）螺内酰胺和酰胺的化合物，其化学式如下（I）（Ia）和（Ib）。更具体地，本发明的化合物是H3受体调节剂，因此在治疗和/或预防包括与中枢神经系统相关的多种疾病在内的由H3受体调节的疾病中特别有用。此外，本发明还公开了取代苯基环烷基吡咯烷（哌啶）螺内酰胺和酰胺的制备方法，以及其中间体。